TheNote.app
STAT | Reporting from the frontiers of health and medicine

STAT+: FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt

The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular dystrophy to some patients.
favicon
statnews.com
statnews.com
Image for the article: STAT+: FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt
RSS Hunter
© 2015-2025, TheNote.app
· Privacy Policy · Terms & Conditions · Contact · Android iOS MacOS